Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-07-11
2010-12-28
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S172000, C514S026000, C514S025000
Reexamination Certificate
active
07858604
ABSTRACT:
A method of treating volume expansion mediated hypertension including administering a therapeutically effective dose of resibufogenin to a patient having volume expansion mediated hypertension. A method for the determination of the presence of volume expansion mediated hypertension may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does exist, concluding that volume expansion mediated hypertension does exist. The method may advantageously be practiced by employing urine, blood serum or blood plasma as the body specimen in determining whether a patient has volume expansion mediated hypertension. In another embodiment, bufodienolide derivatives other than resibufogenin may be employed in lieu of thereof or in combination therewith. In another embodiment, resibufogenin analogues may be employed in the treatment of volume expansion mediated hypertension.
REFERENCES:
patent: 4380624 (1983-04-01), Wiesner et al.
patent: 5770376 (1998-06-01), Bagrov
patent: 6251611 (2001-06-01), Puschett
patent: 2008/0261928 (2008-10-01), Puschett
patent: WO 2006/120472 (2006-11-01), None
U.S. Appl. No. 09/990,432, filed Nov. 21, 2001, Jules B. Puschett.
U.S. Appl. No. 10/109,203, filed Mar. 28, 2002, Jules B. Puschett.
U.S. Appl. No. 60/444,730, filed Feb. 4, 2003, Jules B. Puschett.
U.S. Appl. No. 60/619,969, filed Oct. 19, 2004, Jules B. Puschett.
U.S. Appl. No. 60/698,450, filed Jul. 12, 2005, Jules B. Puschett.
Chen et al., “Volume Expansion-Induced Changes in Renal Tubular Membrane Protein Phosphorylation”, Biochem. Biophys. Res. Commun. 143:pp. 74-80 (1987).
Pridijian et al., “Neutralization of marinobufogenin normalizes blood pressure in a rat model of preeclampsia”, J Soc Gynecol Invest 11(Suppl):260A, 2004.
Cai et al., “Down-Regulation of Phosphorylation of Renal Proximal Brush Border Membrane Protein in DOCA-Salt Hypertensive Rats”, J Am Soc Nephrol 5:S26 (1994).
Vu et al., “Involvement of Marinobufagenin in a Rat Model of Human Preeclampsia”, Am J Nephrol 2005;25:520-528 (2005).
Vu et al., “Resibufogenin reduces blood pressure in a rat model of preeclampsia”, Journal of Investigative Medicine, vol. 53, No. 2, Mar. 2005, p. S367.
Lanz et al., “Angiotensin II regulates 11beta-hydroxysteroid dehydrogenase type 2 via AT2 receptors”, Kidney International, vol. 64, No. 3, Sep. 2003, pp. 970-977.
Eckert Seamans Cherin & Mellott , LLC
Kim Jennifer M
Marmo, Esquire Carol A.
Scott & White Healthcare
LandOfFree
Method of treating human volume expansion mediated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating human volume expansion mediated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating human volume expansion mediated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169132